The somatostatin receptor 5 (SSTR5) gene is a candidate gene for bipolar affective disorder (BPAD) as well as for other neuropsychiatric disorders. The gene is positioned on chromosome 16p13.3, a region that has been implicated by a few linkage studies to potentially harbor a disease susceptibility gene for BPAD. Recent evidence shows that the dopamine D2 receptor (DRD2) and SSTR5 interact physically to form heterodimers with enhanced functional activity. Brain D2 dopamine receptors are one of the major targets of neuroleptic treatments in psychiatric disorders. In this study we systematically screened the promoter and coding region of the SSTR5 gene for genetic variation that could contribute to the development of neuropsychiatric disorders. Eleven novel single nucleotide polymorphisms (SNPs) were identified including four missense SNPs, Leu48Met, Ala52Val, Pro109Ser and Pro335Leu. We carried out an association study of BPAD using 80 Danish cases and 144 control subjects, and replication analysis using 55 British cases and 88 control subjects. For the Danish population, association was suggested between silent SNP G573A and BPAD (P = 0.008). For the British population we found association to BPAD with missense mutation Leu48Met (P = 0.003) and missense mutation Pro335Leu (P = 0.004). The statistical significance of the association was, however, greatly reduced after correcting for multiple testing. When combining genotypes from Leu48Met and Pro335Leu into haplotypes, association to BPAD was found in the British population (P = 0.0007). This haplotype association was not replicated in the Danish population. Our results may indicate that the SSTR5 gene is involved in the etiology of BPAD or may exist in linkage disequilibrium with a susceptibility gene close to SSTR5. However, given the marginal statistical significance and the potential for false-positive results in association studies with candidate genes, further studies are needed to clarify this hypothesis.
Introduction
In 1995 Ewald and co-workers 1 found evidence for the existence of a bipolar susceptibility locus on chromosome 16p13.3 in two Danish families segregating bipolar affective disorder (BPAD). The highest lodscore (2.52) was obtained for marker D16S510 (9 cM on Genethon map) 2 when combining the two families and assuming a recessive mode of inheritance. 1 Positive lodscores were also obtained with surrounding markers supporting that a susceptibility locus for bipolar disorder may exist distal on chromosome 16p. Weak support for this finding was found in a study of 97 bipolar families of the NIMH Genetics Initiative, 3 and
Correspondence: M Nyegaard, MSc, Department of Clinical Biochemistry and Genetics, KKA, Odense University Hospital, 5000 Odense C, Denmark. E-mail: mette.nyegaardȰouh.fyns-amt.dk in a genome-wide scan in two Costa Rican families with BPAD. 4 Furthermore an increased prevalence of psychiatric diagnosis especially mood disorder was found in 13 patients with Rubinstein-Taybi syndrome, a multiple congenital anomaly syndrome mapped to 16p13.3. 5 A number of studies have, however, not been able to replicate linkage between BPAD and markers on 16p13.3 and some studies have even found evidence against linkage to BPAD on 16p13.3. [6] [7] [8] [9] [10] [11] [12] A number of these studies have, however, not reported results assuming a recessive mode of inheritance. 13 The somatostatin receptor 5 (SSTR5) gene is a positional and functional candidate gene for BPAD. The gene has been mapped to chromosome band 16p13.3 by in situ hybridization 14 and radiation hybrid mapping. 15 The SSTR5 mediates the effects of somatostatin, a multi-functional neuroendocrine hormone originally isolated more than 20 years ago from the hypothalamus as a peptide that inhibited the release of growth hormone. 16 Somatostatin is widely distributed throughout the central nervous system, and plays a major role in neurotransmission, glandular secretion, smooth muscle contractility, and cell proliferation. 17 Somatostatin is known to function as a neuropeptide with secretion intimately related to the regulation of other classical neuropeptides and neurotransmitters. It increases the turnover of cholinergic and monoaminergic neurotransmitters and additionally modulates their release. In turn, somatostatin release is stimulated by dopamine, and appears to be stimulated by acetylcholine and inhibited by gamma-amino-butyric acid (GABA). 18 It has been proposed that the somatostatin system may be involved in neurodegenerative and/or affective disorders. In animals a wide spectrum of behavioral and physiological functions is related to somatostatin, including learning, regulation of slow wave sleep and REM sleep, food consumption, and locomoter activity, 18 all of which are often altered in manic or depressed patients. In addition, several investigators have reported a reduction in somatostatin concentration in the cerebrospinal fluid of patient with neuropsychiatric disorders, particularly Alzheimer's disease and depression, but also Parkinson's disease, senile dementia, multiple sclerosis, and schizophrenia. 18, 19 SSTR5 is a member of the somatostatin receptor family encompassing four other subtypes SSTR1-4. All receptor subtypes are 7-transmembrane G-protein coupled receptors having a high degree of sequence similarity within the 7-membrane spanning alphahelix segment but diverge in their amino-and carboxytermini. The receptors display an overlapping but characteristic pattern of expression that is sub-type and tissue specific. 17 The SST5 receptor is expressed in the brain, in the pituitary gland in adults and in the pituitary and hypothalamus in the fetus. 20 The SSTR5 gene contains no introns and was cloned in 1993. 21, 22 Recently, it has been shown that the somatostatin receptor 5 interacts physically with the long form of the dopamine D2 receptor through hetero-oligomerization to create a novel receptor with enhanced functional activity. 23 Hetero-oligomerization leads to synergy such that the binding affinity for the second ligand is increased as a result of receptor occupancy of the first ligand. This receptor complex, simultaneously occupied by two ligands, appears to be the most accelerating signaling form. This newly characterized functional interaction between dopaminergic and somatostatinergic neurotransmission increases the interest for SSTR5 as a candidate gene for affective disorders and other neuropsychiatric disorders, as dopamine D2 receptor (DRD2) antagonists are currently being used in the treatment of manic symptoms and schizophrenia.
In this study the following investigations were performed: (1) we determined the position of SSTR5 on the genetic map and compared this with the region suggested by linkage findings on BPAD; (2) we searched for single nucleotide polymorphisms (SNPs) in the SSTR5 gene; (3) we performed haplotype analysis in two Danish families transmitting BPAD with suggestive linkage to region 16p13.3; and (4) we carried out an association study with BPAD in two case-control samples.
Materials and methods

Detection of genetic variation
Five affected individuals with bipolar I disorder according to DSM-IV 24 from two Danish families transmitting BPAD were selected for mutation screening. These individuals were IV-20, VI-1, III-25, and V-2 from family 4 and III-2 from family 2. 1 The affected individuals were selected from different sub branches of the pedigrees, as genetic heterogeneity and phenocopies may exist even within each pedigree. Positive linkage was obtained using a recessive mode for disease transmission, and therefore 'married-into' chromosomes that were transmitted to affecteds were considered important to screen for variations. Two healthy individuals recruited among laboratory staff were included in addition. The 5Ј-promoter region (2258 bp immediately upstream of the ATG start codon, Genbank accession No. U18976) and the complete coding region (1092 bp, Genbank accession No. D16827) of the SSTR5 gene were systematically screened for genetic variation using direct cycle sequencing of genomic DNA. For each individual two overlapping fragments (fragments A and B) were amplified from genomic DNA using primers and reaction conditions described below. Direct cycle sequencing was performed by the dideoxy nucleotide chain termination method 25 using the Dye Termination Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequencing was performed on both strands.
PCR amplification
Fragment A and fragment B, together containing the total set of SSTR5 SNPs, were separately amplified using PCR. Each PCR reaction mix contained genomic DNA (50 ng), 4 pmol of each primer, 0.35 mM dNTP, Expand Long Template enzyme mixture (1 U, Roche Diagnostics, Mannheim, Germany) and buffer system 1 supplied by the manufacturer, in a total volume of 10 l. Primer sequences for fragment A were Afor: 5Ј-tctctggaccttgtgccag (nt pos 1-20 Genbank accession No. AF152962) and Arev: 5Ј-ggccactgccaggttgagaa (nt pos 286-305 Genbank accession No. D16827). The primer sequences for fragment B were Bfor: 5Ј-atgtgctggttcagggactc (nt pos 2178-2197 Genbank accession No. AF152962) and Brev: 5Ј-tgactggcaggtcatgggtg (nt pos 1213-1232 Genbank accession No. D16827). PCR was performed using 30 cycles of 94°C for 45 s, 60°C for 40 s and 68°C for 2 min. After PCR, 6 l of fragment A and 6 l of fragment B were pooled and purified from unincorporated dNTPs and primers adding 1 U of SAP (USB, Cleveland, OH, USA) and 2 U of ExoI (New England Biolabs, Beverly, MA, USA). The reactions were incubated at 37°C for 60 min followed by 85°C for 15 min.
Single basepair extension
Primers for single basepair extension (SBE) were designed to terminate on the base 5Ј to the SNP and to avoid containing any neighboring SNPs. The length of the primers was adjusted to 18, 22, 24, 26, 30, 32, 34, 36, 38, 42 , by adding a random sequence to the 5Ј-end (Table 1) . Multiplex SBE were carried out in a volume of 5 l using 2.5 l SNaPshot mix (Applied Biosystems), 2 l of pooled purified fragment A and fragment B, 1 pmol of SBE primer SNP1, SNP8, 0.3 pmol of SNP4, SNP5, SNP6, SNP7, SNP9, SNP10, SNP11, and 0.05 pmol of SNP3. Thirty cycles of 94°C for 10 s, 50°C for 8 s, and 60°C for 30 s were performed. To remove excess ddNTPs, 1 U of SAP (USB) was added and the reactions were incubated at 37°C for 60 min followed by 85°C for 15 min. Samples were assayed by electrophoresis on a ABI377 sequencer using a 12% denaturing polyacrylamide gel.
SNP2 detection
For detection of SNP2 (1 bp deletion), primer R11 (5Ј-catttggcttctgtctaagg nt pos 196-215 Genbank accession No. AF152962) was end-labeled using polynucleotide kinase (Amersham Pharmacia Biotech, Uppsala, Sweden) and [␥-
33 P]ATP. PCR was performed using primer set Afor/R11 and the fragments (215 vs 214 bp) were resolved on a 6% denaturing polyacrylamide gel. Autoradiography was performed for 1-2 days at room temperature.
Genetic fine mapping
For linkage mapping, family members from seven informative pedigrees (CEPH pedigree Nos 102, 884, 1331, 1347, 1362, 1413, and 1416) were genotyped for SNP2 and SNP11. To increase marker informativity, genotypes from the two polymorphic sites were combined into haplotypes. Multipoint linkage analysis was carried out using the program CMAP from the LINK-AGE package, 26 and data on chromosome 16 markers from the CEPH database 8.2 (www.cephb.fr/cephdb/). After analysis, recombination frequencies were con- 
Each SNP was assigned a nucleotide position relatively to the first base in the coding sequence (position 1).
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verted to genetic distances in Morgans using the Kosambi mapping function. All distances are sex-averaged distances.
Association study
Two case-control samples were included in the study. The first sample (DK) consisted of 80 Danish Caucasian bipolar patients and 144 ethnically matched controls. The Danish patients were recruited from the Psychiatric Hospital in Aarhus, and interviewed using the semi-structured interview 'Schedules for Clinical Assessment in Neuropsychiatry'. All cases were diagnosed as bipolar 1 according to DSM-IV. 24 The 144 Danish control individuals were blood donors assigned through the blood bank in Odense. They were not interviewed or screened to exclude subjects with a history of psychiatric illness prior to the assessment. The second sample (UK) consisted of 55 British Caucasian bipolar patients and 88 ethnically matched controls. The British patients were recruited from three Lithium therapy clinics at the Institute of Psychiatry, London, Epsom General Hospital and Northern General Hospital, Sheffield. The patients were given a best-estimate lifetime diagnosis according to DSM-IV criteria on the basis of hospital case-notes and structured interviews (SADS-L, SCAN). Control subjects were Caucasian volunteers from UK recruited from general practices and were screened with a brief semi-structured interview to ascertain the absence of psychiatric illness. All control individuals scored higher than 25 points in the minimental state examination.
Statistical analysis
Chi-square statistics were used to test the null hypothesis of no difference in the allele frequency for patients and controls. The chi-square values and corresponding two-sided P-values were calculated using the program CONTING v.2.30. 27 When expected numbers were less than 5, Fishers exact test was applied, and the twosided P-values were calculated using the program 2BY2 v.1.50. 27 For interesting two-locus (SNP6-SNP11) haplotype, CLUMP v.1.6 was used to estimate significance. 28 CONTING, 2BY2, and CLUMP were found at URL:http://linkage.rockefeller.edu/soft/ (2BY2 and CONTING were found under LINKAGE UTILITY PROGRAMS).
Linkage disequilibrium and Hardy-Weinberg equilibrium
The degree of linkage disequilibrium between pairs of SNPs was calculated for the Danish control sample (144 subjects). For each set of SNPs, genotypes were combined into haplotypes and haplotype frequencies were calculated using the program EH v.1.14 (URL: http://linkage.rockefeller.edu/soft/). 27 From haplotype frequencies, the degree of linkage disequilibrium (D) and the fraction (DЈ), called the standardized linkage disequilibrium, of the maximum possible value of D at the given allele frequencies, was calculated. 29 We used the chi-square values for allelic association, calculated by the EH-program, to determine if the DЈ value was statistically significant (if the null hypothesis of no linkage disequilibrium could be rejected). We used a significance level of 0.05. Deviation from Hardy-Weinberg (HW) equilibrium was tested using the program HWI v.2.10 (URL: http://linkage.rockefeller.edu/ soft/). 27 When expected numbers were less than 5, the exact significance probability was used, calculated by Stata (URL: http://stata.com/). A significance level of 0.05 was used.
Discrepancies were found in the 5Ј-upstream region compared to accession No. U18976 during sequence analysis. A revised 5Ј-upstream sequence was submitted to GenBank under accession No. AF152962.
During the completion of this manuscript, the Human Genome Project identified two SNPs in the SSTR5 gene as base pair discrepancies during alignment of overlapping clones (SNP rs169068 and rs642249 at http://www.ncbi.nlm.nih.gov/SNP/). The SNPs are not yet validated. SNP rs169068 is identical to SNP11 in this manuscript.
Results
Genetic variation
Eleven previously unknown SNPs in the 5Ј-upstream (2258 bp) and the coding region (1092 bp) of the SSTR5 gene were identified from five psychiatric patients and two unrelated healthy individuals ( Table 1) . Nine of the SNPs were found in the affected individuals. In the 5Ј-flanking region, that formerly has been sequenced and shown to contain a functional promoter, 30 five SNPs were found: T-2187G, −2134delT, A-1665G, C-801G, and T-461C. In the coding region four SNPs introducing an amino acid change were found: Leu48-Met, Ala52Val, Pro109Ser and Pro335Leu. In addition two silent SNPs were found: G573A and C633T.
To elucidate whether the SNPs in the 5Ј-upstream region were located in transcription factor binding sites, we ran the complete 5Ј-upstream region through the program MatInspector 2.1 (URL: http://www.gfs. de.biodv/software). 31 The program located consensus matches in nucleotide sequences using a library of 280 known transcription factor binding sites. SNP3 and SNP5 were located in the core sequences of two different promoter element-binding sites, while no known promoter element sites were predicted to include SNP1, SNP2, and SNP4. The T-allele (allele 1) of SNP3 (A-1665G)/(T-1665C) (+strand/ −strand) interrupts the core sequence (CGGA) of the CETS1P54 binding site on the anti-sense (−) strand. The C-allele (allele 2) of SNP5 (T-461C) was found to interrupt the core sequence (CCAT) of the YY1 binding site on the sense (+) strand.
Genetic fine mapping
A reference map of 16 markers covering the telomeric region of chromosome 16 p was used including the following six markers: telomere-D16S521-5.0 cM-D16S3024-0.6 cM-D16S3070-0.8 cM-D16S3072-1.6 cM-D16S510-0.1 cM-D16S423 ( Figure 1 ). The order of this map is supported by odds of at least 1000:1. 2 A CMAP multipoint analysis placed the SSTR5 gene in the 5.0 cM interval between D16S521 and D16S3024. A peak location score of 95.6 was seen between these two markers, corresponding to a multipoint lodscore of 20.8. This position was favored over the second most likely position (telomeric to D16S521) by odds 1540:1. All other locations could be ruled out by odds greater than 100 000:1.
HW and linkage disequilibrium
Deviation from HW equilibrium was found for SNP8 in the DK case sample and for SNP3, SNP4, and SNP10 in the DK control sample (significance level 0.05). In addition deviation from HW equilibrium was found for SNP7 and SNP8 in the UK case samples. We performed 46 (2 × 11 + 2 × 10) tests for deviation from HW equilibrium (SNP2 was not analyzed in the UK cases and UK controls). The tests performed were not independent due to linkage disequilibrium, although for comparison, in 46 independent tests approximately two Type 1 errors are expected at a 5% significance level. Using the Bonferroni correction for multiple testing
n , where n is the number of independent tests carried out, the most extreme P-value in the DK control sample (0.001 for SNP4) increased to 0.05 in 46 tests. Hence, the deviation from HW equilibrium for SNP4 was significant after correction. It should be noted that the majority of SNPs found to be out of HW equilibrium were SNPs with a minor allele frequency of less than 7-8%.
Complete linkage disequilibrium was found between approximately half of the pairs of SNPs in the DK control sample. The other half of SNPs displayed a lower degree of linkage disequilibrium and for a small subset of loci (SNP4/SNP6 SNP4/SNP7, SNP4/SNP8, SNP5/SNP7, and SNP5/SNP8), almost complete linkage equilibrium was found (Figure 2 ). For all pairs of SNPs the statistical significance of the DЈ value was calculated. Approximately half of the DЈ values were statistically significant. In Figure 3 , significant DЈ values are shown as a function of distance in base pairs between SNPs. It is clear that even though strong significant linkage disequilibrium exists between SNPs in the SSTR5 gene, linkage disequilibrium is not complete across the region.
Haplotype segregation in families transmitting BPAD Family members, from whom DNA was available, were genotyped for SNP1-11 and 11-locus haplotypes were constructed. Haplotypes, which could not be determined unambiguously, were considered unknown and left out of the analysis. By visual inspection of the pedigrees and considering both healthy and affected individuals, nine different haplotypes (named H1-H9) were found to segregate within the two families. Eight of these haplotypes were found in affecteds. As the disease mechanism is expected to be recessive (highest lodscores were obtained in the recessive disease Molecular Psychiatry model), we also counted the number of chromosomes and haplotypes which were married-into the family (ie non-IBD) and present among affected family members. Chromosomes IBD were discarded to avoid accumulation of haplotypes in affecteds due to familial relationship. From this analysis, four haplotypes (H1, H3, H7, and H8) were repeatedly found in affecteds. Together these four haplotypes account for 12 out of 16 'married-into' chromosomes in affecteds. We compared the haplotype distribution in affecteds with the haplotype distribution in the background population. The haplotype frequencies for the background population were estimated from the DK control sample (144 control individuals) using the program EH v.1.14 ( Table 2) . 27 The absolute number of haplotypes in the DK control sample was calculated by multiplying relative frequency with the number of control chromosomes (288) ( Table 2 ). A significant difference was obtained (P 1 = 0.038) when the distribution of haplotypes in affected family members and in the back- Haplotype frequencies in affected family members and the background population are shown. Because of a putative recessive disease mechanism, only haplotypes 'married-into' the families were considered. Four different haplotypes were repeatedly observed in affecteds (indicated in bold).
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ground population was compared using CLUMP v.1.6.
28
Association study
The DK case-control sample was genotyped with respect to SNP1-SNP11 and a significant difference (significance level 0.05) in allele frequencies between cases and controls was found for SNP9 (P = 0.008). SNP9 is a silent variation in the coding region. The UK case-control sample was genotyped with respect to SNP1 and SNP3-11. Differences in allele frequencies were found for SNP6 (P = 0.003) and SNP11 (P = 0.004) ( Table 3) , both missense mutations. We combined genotypes from SNP6 and SNP11 into haplotypes for UK and DK cases and controls. For the UK population, the following numbers of haplotypes were observed (haplotype 1-1, 1-2, 2-1, and 2-2): 34(37%), 57(62%), 1(1%) and 0(0%) for cases and 74(45%), 71(43%), 19(12%), and 0(0%) for controls. This difference was significant (P 1 = 0.0007) using CLUMP. 28 This haplotype association was not replicated in the Danish casecontrol sample, showing the following haplotype distribution: 62(39%), 83(52%), 11(7%), and 2(1%) for cases and 82(40%), 108(53%), 14(7%) and 0(0%) for controls.
Discussion
This is the first report of a systematic search for polymorphisms in the SSTR5 gene in psychiatric patients.
By sequencing the promoter and coding region of the SSTR5 gene (3350 bp in total) on 14 chromosomes, we have identified 11 previously unknown sequence variants. Two additional polymorphic sites in the 5Ј-upstream region have been described by Sasi et al. 32 These polymorphisms were not found in our screening sample.
Linkage disequilibrium
To estimate linkage disequilibrium between pairs of SNPs we used Lewontin's DЈ. 29 DЈ has been shown to be reasonably robust towards differences in allele frequencies in contrast to D. 33 Large differences in the degree of linkage disequilibrium were found within the SSTR5 gene, with ͉DЈ͉ ranging from 1 to 0.01. A cluster of SNPs displayed strong linkage disequilibrium within the coding region. However, only approximately half of the DЈ values calculated in this study were statistically significant (the H null hypothesis of no linkage disequilibrium could be rejected). This is most likely due to the low allele frequency for the minor allele for many of the SNPs identified in this study. For pairs of polymorphisms where either one or both loci have a very rare allele, a much larger number of observations is needed to reject the null-hypothesis of no linkage disequilibrium, than for sets of loci with more common alleles. 33 It is clear that a substantial decline in linkage disequilibrium has occurred within the SSTR5 gene. It may therefore seem reasonable to include a number of SNPs in future association studies 34 It is not yet fully understood which underlying population genetic mechanisms are responsible for the extent of linkage disequilibrium within genes. Genetic drift, selection pressure, the temporal history of mutation events, variation in recombination rates in different genomic regions, and sampling, which might by chance remove certain haplotypes, are components that affect linkage disequilibrium.
Promoter SNPs
Two SNPs in the 5Ј-upstream region (SNP3 and SNP5) were found to be located in the core sequences of promoter element-binding sites CETS1P54 and YY1 respectively. Polymorphisms in promoter elementbinding sites may affect the transcription level of the SSTR5 gene. None of these SNPs showed association to BPAD.
Missense SNPs
Of the four missense substitutions, the Leu48Met (SNP6) and the Ala52Val (SNP7) substitutions are Molecular Psychiatry minor protein chemical changes. Ala and Val residues are small hydrophobic amino acids, and Leu and Met residues are large hydrophobic amino acids. It can, however, not be excluded that minor protein chemical changes may have an effect on binding affinity or receptor stability. In the presenilin-1 gene, two different Ala to Val substitutions were identified in four unrelated patients with early onset Alzheimer's disease. 35 In these patients, the Ala to Val substitutions were positioned in the N terminal region and in a transmembrane (TM) region respectively, the latter mutation predicted to interfere with the alpha helix structure. The Leu48Met (SNP6) and the Ala52Val (SNP7) missense substitutions in the SSTR5 gene are both located in the predicted TM domains (Figure 4) . We found association to BPAD with SNP6 in the UK population. The other two missense mutations, Pro10-9Ser (SNP8) and Pro335Leu (SNP11) substitution are non-conservative amino acid changes. Pro has a rigid cyclic structure, and is often observed in turns between helices. As Pro is often of structural importance and has no structural similar counterpart, it is possible that the Pro substitutions involve a stability or structure change of the receptor. The Pro109Ser substitution was found in extra-cellular loop 1 (ECLI) and the Pro335-Leu substitution was found in the C-terminal intra- cellular part of the receptor (Figure 4 ). According to an alignment of the five different somatostatin receptors (SSTR1-5), 36 a proline in position 335 in the C-terminal part is conserved in four of the five receptor subtypes (SSTR1, 3, 4 and 5). The Pro335Leu (SNP11) showed association to BPAD in the UK population. Mutation analysis of SSTR5 involving C-tail truncation has shown that a positive molecular internalization signal is contained within the C-terminal segment, including Pro335. 37 Fine mapping SSTR5 is a positional and functional candidate gene for bipolar affective disorder. Ewald and coworkers 1 found in two Danish bipolar pedigrees suggestive linkage to a 10-cM broad chromosome region on 16p13.3. In these two families a combined lodscore of 2.65 was found for marker D16S510 (9 cM on Genethon map). 2 In the larger family alone, lodscores of 1.60 and 1.76 were found with D16S85 (HBA1) (0 cM, not on Genethon map) and D16S510 respectively. The lodscore at D16S521 (0 cM on Genethon map), 2 which was positioned in between D16S85 and D16S510 on the map used by Ewald et al (1995) , dropped to −0.57. Interestingly, a BLAST search against the finished human genome sequences (http://www.ncbi.nlm.nih.gov/ genome/seq/) using D16S85 and D16S521 suggested that the order of these two markers are reversed compared to the map used by Ewald et al.* This revised marker order gives consistent positive lodscores within the 16p13.3 region. The genetic mapping result presented here showed that the SSTR5 gene is located 3 cM centromeric to D16S521 and 2 cM telomeric to D16S3024 (Figure 1 ). This position is within the region implicated by linkage studies, and close to marker D16S85.
The fine mapping results showed in addition that SSTR5 is located in a region with suggestive linkage to panic disorder, 38 and autism, 39 and may be a candidate * D16S85 was found on compound Z69706 and D16S521 was found on compound Z69719, both on contig NT 000655, at URL: http://www.ncbi.nlm.nih.gov/genome/guide/HsChr16.shtml.
gene for these disorders. In the study of panic disorder the highest lodscore on chromosome 16 was obtained with marker D16S423 (9 cM on Genethon map), 2 which was the most telomeric marker analyzed in that study. 38 In a study of autism, positive lodscores were obtained in the region D16S423-D16S405 (30 cM on Genethon map). 2, 39 The position of SSTR5 on the genetic map and on Genemap99 (marker STSG39114 on the the GB4 radiation hybrid map, http://www.ncbi.nlm.nih. gov/genemap99/) 15 is in agreement.
Haplotypes in families transmitting BPAD
When evaluating the segregation of SSTR5 haplotypes in the disease families, we used a family-based association approach. This was done as the linkage results pointing to a candidate gene for BPAD at chromosome region 16p13.3 were obtained in a recessive mode of transmission (although the region received some support in a dominant mode of transmission as well). 40 When evaluating haplotypes it was clear that affected family members did not consistently carry two identical haplotypes. This was albeit not expected for a complex heterogenic disorder. In the study we considered haplotypes that had been passed on to affected offsprings, discarded haplotypes IBD. This was done to avoid overrepresentation of certain haplotypes solely due to familial relationship, but unfortunately this also reduced the number of haplotypes within the study. Sixteen non-IBD chromosomes were present in affecteds in the two families. Four haplotypes (H1, H3, H7, and H8) were present three times each in affecteds. For haplotypes H3 and H8, this was more than twice as often as expected (19% and 19% in affecteds vs 5% and 9% in the background population), whereas the frequencies of haplotype H1 and H7 were similar to the background population (19% and 19% in affecteds vs 18% and 17% in the background population). Together the four haplotypes (H1, H3, H7 and H8) accounted for 12 of the 16 non-IBD chromosomes seen in affecteds. Interestingly, the four haplotypes were pair wise very similar. H1 and H3 differed only at one SNP. H7 and H8 differed at another SNP. It is possible that H1 and H3 originally were the same haplotype, and that a sequence change took place on a H1 haplotype, thus forming a new and rare haplotype (H3). The same applies for H7 and H8. If a possible susceptibility variation were present on a certain haplotype before these sequence changes took place, several haplotypes in a population would carry that susceptibility gene or mutation. This may be the case for H1, H3, H7 and H8 in the two Danish disease families. The difference in haplotype distribution between affecteds and the background population was significant (CLUMP P 1 = 0.038).
Association study
In the DK case-control sample allelic association to BPAD was found with SNP9 (allele 2), a synonymous sequence change (P = 0.008). The association was not replicated in the UK sample. Allele 2 was initially identified in a control individual, and not found in any of the family members from the two Danish disease families. This indicates that the significant association could be a false positive finding, although this cannot be concluded with certainty.
In the UK sample significant association to BPAD was found with SNP6 (allele 1) (P = 0.003) and with SNP11 (allele 2) (P = 0.004). Combining genotypes from these two SNPs into haplotypes, the significance increased to P = 0.0007. This haplotype association was not replicated in the Danish case-control study. Within the two Danish families transmitting BPAD, allele 1 from SNP6 and allele 2 from SNP11 were present on haplotype H7. H7 was seen with a frequency of 19% in affecteds and 17% in the background population. It is dubious if the Danish haplotype study supports the British association.
We are aware though, that the association between BPAD and SSTR5 may be a false-positive result. As with many association studies, multiple testing is a major issue. The number of tests carried out, combined with the low prior probability of pointing out the right gene from a number of potential candidates, increases the risk of getting a false-positive result.
Using the Bonferroni correction for multiple testing P corr = 1 − (1 − P) n , where n is the number of independent tests carried out, a P value of 0.003 increases to P corr = 0.06 in 21 tests (11 tests in Danish case-controls, 10 tests in British case-controls). Thus, none of the single SNP P-value remains significant after correction. This is, however, a very conservative correction as some of the SNPs are in linkage disequilibrium and therefore the tests are not independent. Currently there is no good method for adjusting P-values for multiple testing when loci involved are in strong linkage disequilibrium.
A major problem is that we do not know how much signal to expect, when analyzing potential susceptibility genes for BPAD and other complex disorders, where a substantial degree of heterogeneity is expected to exist. Power calculations show that detecting associations with alleles having frequencies under 5% will typically require thousands of patients (except in rare cases in which the attributable risk is large). 41 Long and Langley (1999) indicate that there is sufficient power to detect the presence of causative polymorphisms of small effects if on the order of 500 individuals are sampled. 42 Compared to the number of individuals mentioned above our samples are relatively small.
Martin and coworkers have carried out as SNP analysis of the APOE in Alzheimer's disease, to investigate whether it was possible to detect association near a complex disease gene using SNPs. 43 They used 60 SNPs spanning 40 kb on either side of APOE in 220 cases and 220 controls. They found that looking for regions of markers with P values nearing significance for association (significance level 0.05 without correction for multiple testing) is an important indicator for the presence of a disease gene.
Considering the new results revealing that SSTR5 and DRD2 form functional heterodimers, it is not unlikely that the impact of an SSTR5 mutation is Molecular Psychiatry influenced by the presence of DRD2 mutations. It is possible that SNP6 and SNP11 truly increase susceptibility to BPAD in the UK population, perhaps in combination with other (unknown) susceptibility loci found more commonly in the UK population than in the Danish population. Alternatively, strong linkage disequilibrium may exist between SSTR5 and one or several susceptibility alleles in a gene close to SSTR5. These susceptibility alleles for BPAD could be located on different SSTR5 haplotypes.
In view of the prior evidence from linkage analysis, altered somatostatin level in bipolar affected patients, physical interaction between the SST5 receptor and D2 receptor and a cluster of markers in the SSTR5 gene with P-values nearing significance level, we suggest that SSTR5 may be a susceptibility gene for BPAD. Further studies with additional samples and inclusion of DRD2 polymorphisms will clarify this. Finally, the possible significance of SSTR5 gene variants in other neuropsychiatric diseases should be investigated.
